Bourgeon Capital Management’s ARK Genomic Revolution ETF ARKG Stock Holding History

Bourgeon Capital Management’s Portfolio ARKG Stock Details ARKG Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q1	–	Sell	-36	Closed	-$1.19K	–	126
2023 Q4	$1.19K	Hold	36	–	–	﹤0.01%	327
2023 Q3	$1.01K	Hold	36	–	–	﹤0.01%	311
2023 Q2	$1.24K	Hold	36	–	–	﹤0.01%	301
2023 Q1	$1.09K	Hold	36	–	–	﹤0.01%	288
2022 Q4	$1.02K	Sell	36 -94	-72%	-$2.98K	﹤0.01%	324
2022 Q3	$4K	Hold	130	–	–	﹤0.01%	270
2022 Q2	$4K	Hold	130	–	–	﹤0.01%	255
2022 Q1	$6K	Hold	130	–	–	﹤0.01%	245
2021 Q4	$8K	Hold	130	–	–	﹤0.01%	225
2021 Q3	$10K	Hold	130	–	–	﹤0.01%	227
2021 Q2	$12K	Hold	130	–	–	﹤0.01%	223
2021 Q1	$12K	Buy	130 +118	+983%	+$11.7K	﹤0.01%	221
2020 Q4	$1K	Buy	+12	New	+$956	﹤0.01%	255

Other funds holding ARKG

MMEA

Main Management ETF Advisors San Francisco, California $3.3B AUM 33.88% 1-Year Est. Return

BNP Paribas Financial Markets Paris, France $289B AUM 60.46% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Wells Fargo San Francisco, California $617B AUM 30.33% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

LPL Financial San Diego, California $445B AUM 25.58% 1-Year Est. Return

Citigroup New York $303B AUM 53.02% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

State of Wisconsin Investment Board Madison, Wisconsin $49.6B AUM 39.59% 1-Year Est. Return

Bourgeon Capital Management's ARKG Position: Q1 2024 in Review

Bourgeon Capital Management sold out of ARK Genomic Revolution ETF (ARKG) in Q1 2024, closing a stake of 36 shares — an estimated $1.19K sold.

Bourgeon Capital Management first reported a position in ARKG in Q4 2020 and held it in 13 quarters. The position peaked at $12K in Q2 2021. 286 funds tracked by Wall St. Rank hold ARKG as of Q1 2024.

Bourgeon Capital Management reported no remaining ARK Genomic Revolution ETF position as of Q1 2024 after selling out during the quarter.
Bourgeon Capital Management sold 36 ARK Genomic Revolution ETF shares in Q1 2024, an estimated $1.19K.
Bourgeon Capital Management first reported a position in ARK Genomic Revolution ETF in Q4 2020 and held it in 13 quarters.
Bourgeon Capital Management's ARK Genomic Revolution ETF position peaked at $12K in Q2 2021.
286 funds tracked by Wall St. Rank held ARK Genomic Revolution ETF as of Q1 2024.

Based on Bourgeon Capital Management's 13F filing for Q1 2024, filed 19 Apr 2024.